Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GUTSNASDAQ:NPCENASDAQ:OMNASDAQ:TMCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGUTSFractyl Health$1.91-2.1%$1.67$0.87▼$5.50$95.50M1.85327,737 shs201,675 shsNPCENeuroPace$10.60-1.7%$12.83$5.45▼$18.98$353.57M2.03171,285 shs237,824 shsOMOutset Medical$19.57+3.3%$15.77$5.85▼$72.60$335.66M2.15122,606 shs453,522 shsTMCITreace Medical Concepts$5.46+0.4%$6.43$4.54▼$10.79$342.12M0.68545,495 shs298,190 shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGUTSFractyl Health-6.70%-9.72%+15.38%+54.76%-64.02%NPCENeuroPace-2.80%-16.69%-38.36%-8.26%+65.85%OMOutset Medical-7.43%-8.28%-2.87%+128.83%-66.06%TMCITreace Medical Concepts-5.56%-11.83%-19.05%-33.74%-10.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGUTSFractyl Health2.3665 of 5 stars3.52.00.00.03.30.00.0NPCENeuroPace3.7407 of 5 stars3.45.00.00.02.44.20.6OMOutset Medical1.4666 of 5 stars3.53.00.00.00.00.80.0TMCITreace Medical Concepts1.9539 of 5 stars3.11.00.00.01.33.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGUTSFractyl Health 3.00Buy$11.00475.92% UpsideNPCENeuroPace 2.83Moderate Buy$15.5046.23% UpsideOMOutset Medical 3.00Buy$27.0037.97% UpsideTMCITreace Medical Concepts 2.29Hold$10.1686.03% UpsideCurrent Analyst Ratings BreakdownLatest GUTS, NPCE, OM, and TMCI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025NPCENeuroPaceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.005/21/2025OMOutset MedicalRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSector Perform ➝ Sector Perform$14.00 ➝ $21.005/15/2025OMOutset MedicalScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025NPCENeuroPaceJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$14.00 ➝ $16.005/14/2025NPCENeuroPaceCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$17.00 ➝ $17.005/9/2025TMCITreace Medical ConceptsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.605/8/2025OMOutset MedicalRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$12.00 ➝ $14.004/15/2025GUTSFractyl HealthCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.004/11/2025TMCITreace Medical ConceptsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$9.50 ➝ $8.003/21/2025OMOutset MedicalStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$15.00(Data available from 6/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGUTSFractyl Health$90K1,039.46N/AN/A$0.59 per share3.24NPCENeuroPace$79.91M4.35N/AN/A$0.27 per share39.26OMOutset Medical$113.69M3.05N/AN/A$7.49 per share2.61TMCITreace Medical Concepts$209.36M1.64N/AN/A$1.81 per share3.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGUTSFractyl Health-$68.69M-$1.85N/AN/AN/A-73,864.52%-228.66%-76.74%8/13/2025 (Estimated)NPCENeuroPace-$27.14M-$0.84N/AN/AN/A-29.42%-190.84%-25.08%8/12/2025 (Estimated)OMOutset Medical-$127.98M-$29.15N/A∞N/A-98.74%-143.62%-37.50%8/6/2025 (Estimated)TMCITreace Medical Concepts-$55.74M-$0.85N/AN/AN/A-25.14%-48.69%-24.59%8/5/2025 (Estimated)Latest GUTS, NPCE, OM, and TMCI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025GUTSFractyl Health-$0.49-$0.49N/A-$0.49N/AN/A5/13/2025Q1 2025NPCENeuroPace-$0.26-$0.21+$0.05-$0.21$21.85 million$22.52 million5/8/2025Q1 2025TMCITreace Medical Concepts-$0.31-$0.25+$0.06-$0.25$52.07 million$52.57 million5/7/2025Q1 2025OMOutset Medical-$0.97-$3.66-$2.69-$3.66$27.81 million$29.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGUTSFractyl HealthN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/AOMOutset MedicalN/AN/AN/AN/AN/ATMCITreace Medical ConceptsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGUTSFractyl Health4.612.502.50NPCENeuroPace2.466.635.70OMOutset Medical0.578.376.74TMCITreace Medical Concepts0.514.503.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGUTSFractyl HealthN/ANPCENeuroPace78.83%OMOutset MedicalN/ATMCITreace Medical Concepts84.08%Insider OwnershipCompanyInsider OwnershipGUTSFractyl HealthN/ANPCENeuroPace20.50%OMOutset Medical2.40%TMCITreace Medical Concepts27.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGUTSFractyl Health10248.98 millionN/AN/ANPCENeuroPace17032.80 million26.08 millionOptionableOMOutset Medical52017.72 million17.30 millionNot OptionableTMCITreace Medical Concepts25062.89 million45.46 millionOptionableGUTS, NPCE, OM, and TMCI HeadlinesRecent News About These CompaniesBrokerages Set Treace Medical Concepts, Inc. (NASDAQ:TMCI) Price Target at $10.16June 15 at 2:09 AM | americanbankingnews.comAttention Long-Term Treace Medical Concepts, Inc. (™CI) Shareholders: Grabar Law Office is Investigating Claims on Your BehalfJune 13, 2025 | investing.comTreace Medical Concepts, Inc. (NASDAQ:TMCI) Given Consensus Recommendation of "Hold" by BrokeragesJune 12, 2025 | marketbeat.comKuehn Law Encourages Investors of Treace Medical Concepts, Inc. to Contact Law FirmJune 11, 2025 | prnewswire.comSecurities Lawsuit Alert: Treace Medical Concepts, Inc. (TMCI) Investors - Contact Levi & Korsinsky Before June 10, 2025June 10, 2025 | accessnewswire.comTreace Medical Concepts, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; June 10, 2025 Deadline to file Lead Plaintiff MotionJune 10, 2025 | globenewswire.comSecurities Class Action Lawsuit Filed Against Treace Medical Concepts, Inc. (TMCI) - Levi & Korsinsky Represents ShareholdersJune 10, 2025 | accessnewswire.comTMCI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Treace Medical Concepts, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 10, 2025 | globenewswire.comLost Money on Treace Medical Concepts, Inc. (TMCI)? Join Class Action Before June 10, 2025 - Contact Levi & KorsinskyJune 10, 2025 | accessnewswire.comClass Action Filed Against Treace Medical Concepts, Inc. (TMCI) - June 10, 2025 Deadline to Join – Contact Levi & KorsinskyJune 10, 2025 | globenewswire.comTMCI DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important June 10 Deadline in Securities Class Action - TMCIJune 10, 2025 | accessnewswire.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace MedicalJune 10, 2025 | businesswire.comDid You Lose Money on Treace Medical Concepts, Inc. (TMCI)? Levi & Korsinsky Urges Investors to Act Before June 10, 2025June 10, 2025 | accessnewswire.comFINAL REMINDER TMCI DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Treace Medical Concepts, Inc. Investors to Participate in the Class Action LawsuitJune 10, 2025 | accessnewswire.comLevi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 10, 2025 in Treace Medical Concepts, Inc. Lawsuit - TMCIJune 10, 2025 | prnewswire.comSquarepoint Ops LLC Has $137,000 Stock Position in Treace Medical Concepts, Inc. (NASDAQ:TMCI)June 10, 2025 | marketbeat.comShareholders of Treace Medical Concepts, Inc. (TMCI): Protect Your Rights Before June 10, 2025 - Contact Levi & KorsinskyJune 9, 2025 | accessnewswire.comTMCI FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important June 10 Deadline in Securities Class Action - TMCIJune 9, 2025 | accessnewswire.comTreace Medical Concepts, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – TMCIJune 9, 2025 | globenewswire.comDeadline Soon: Treace Medical Concepts, Inc. ...June 9, 2025 | gurufocus.comTMCI Investors Have Final Opportunity to Lead Treace Medical Concepts, Inc. ...June 9, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy3 Top-Rated Energy Companies Staging Strong RecoveriesBy Nathan Reiff | June 2, 2025View 3 Top-Rated Energy Companies Staging Strong RecoveriesPalantir Scores First $1 Billion Contract; Is It Priced In?By Chris Markoch | May 27, 2025View Palantir Scores First $1 Billion Contract; Is It Priced In?3 Companies to Buy on This Early Cycle RecoveryBy Gabriel Osorio-Mazilli | June 3, 2025View 3 Companies to Buy on This Early Cycle RecoveryGUTS, NPCE, OM, and TMCI Company DescriptionsFractyl Health NASDAQ:GUTS$1.91 -0.04 (-2.05%) Closing price 04:00 PM EasternExtended Trading$1.92 +0.01 (+0.26%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.NeuroPace NASDAQ:NPCE$10.60 -0.18 (-1.67%) Closing price 04:00 PM EasternExtended Trading$10.61 +0.01 (+0.09%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.Outset Medical NASDAQ:OM$19.57 +0.63 (+3.33%) Closing price 04:00 PM EasternExtended Trading$19.68 +0.11 (+0.54%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outset Medical, Inc., a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables. It also provides Tablo Data Ecosystem, including TabloHub, a customer-facing portal; MyTablo, a patient-facing portal; and TabloDash, an internal data analytics platform. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.Treace Medical Concepts NASDAQ:TMCI$5.46 +0.02 (+0.37%) Closing price 04:00 PM EasternExtended Trading$5.59 +0.13 (+2.38%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
